Early identification and standardization of clinical treatments are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation. The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs.
Individualised treatment programs for the treatment and management of early onset of rheumatoid arthritis often include drug therapy, rehabilitation interventions, regular follow-up, and multidimensional management. In recent years, with the development of therapeutically oriented, immune-regulatory therapies and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of chronic rheumatoid arthritis in young children. The platform serves the China International Medical Service System, which combines national and international authorities in the field of autoimmunity and rheumatic immunity to provide the following services to patients: 1. Remote pre-diagnosis: pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2.
Interviews in China: arranging face-to-face diagnostics with authorities, developing personalized treatment plans; 3. Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.
Support for remote pre-diagnosis, visiting interviews, full translation and escort.